S&P 500   4,334.76 (+0.34%)
DOW   33,978.66 (+0.04%)
QQQ   359.17 (+0.35%)
AAPL   176.06 (+0.73%)
MSFT   316.49 (-0.16%)
META   298.41 (-0.22%)
GOOGL   130.60 (+0.27%)
AMZN   131.45 (+1.80%)
TSLA   246.66 (+0.73%)
NVDA   422.80 (+1.61%)
NIO   8.39 (-1.64%)
BABA   87.06 (-1.40%)
AMD   96.86 (+0.69%)
T   15.05 (-0.46%)
F   12.66 (+1.85%)
MU   68.69 (-0.28%)
CGC   0.98 (+17.14%)
GE   111.67 (+0.38%)
DIS   80.78 (-0.58%)
AMC   8.24 (+8.14%)
PFE   32.72 (+0.09%)
PYPL   58.42 (+0.93%)
NFLX   383.75 (+1.04%)
S&P 500   4,334.76 (+0.34%)
DOW   33,978.66 (+0.04%)
QQQ   359.17 (+0.35%)
AAPL   176.06 (+0.73%)
MSFT   316.49 (-0.16%)
META   298.41 (-0.22%)
GOOGL   130.60 (+0.27%)
AMZN   131.45 (+1.80%)
TSLA   246.66 (+0.73%)
NVDA   422.80 (+1.61%)
NIO   8.39 (-1.64%)
BABA   87.06 (-1.40%)
AMD   96.86 (+0.69%)
T   15.05 (-0.46%)
F   12.66 (+1.85%)
MU   68.69 (-0.28%)
CGC   0.98 (+17.14%)
GE   111.67 (+0.38%)
DIS   80.78 (-0.58%)
AMC   8.24 (+8.14%)
PFE   32.72 (+0.09%)
PYPL   58.42 (+0.93%)
NFLX   383.75 (+1.04%)
S&P 500   4,334.76 (+0.34%)
DOW   33,978.66 (+0.04%)
QQQ   359.17 (+0.35%)
AAPL   176.06 (+0.73%)
MSFT   316.49 (-0.16%)
META   298.41 (-0.22%)
GOOGL   130.60 (+0.27%)
AMZN   131.45 (+1.80%)
TSLA   246.66 (+0.73%)
NVDA   422.80 (+1.61%)
NIO   8.39 (-1.64%)
BABA   87.06 (-1.40%)
AMD   96.86 (+0.69%)
T   15.05 (-0.46%)
F   12.66 (+1.85%)
MU   68.69 (-0.28%)
CGC   0.98 (+17.14%)
GE   111.67 (+0.38%)
DIS   80.78 (-0.58%)
AMC   8.24 (+8.14%)
PFE   32.72 (+0.09%)
PYPL   58.42 (+0.93%)
NFLX   383.75 (+1.04%)
S&P 500   4,334.76 (+0.34%)
DOW   33,978.66 (+0.04%)
QQQ   359.17 (+0.35%)
AAPL   176.06 (+0.73%)
MSFT   316.49 (-0.16%)
META   298.41 (-0.22%)
GOOGL   130.60 (+0.27%)
AMZN   131.45 (+1.80%)
TSLA   246.66 (+0.73%)
NVDA   422.80 (+1.61%)
NIO   8.39 (-1.64%)
BABA   87.06 (-1.40%)
AMD   96.86 (+0.69%)
T   15.05 (-0.46%)
F   12.66 (+1.85%)
MU   68.69 (-0.28%)
CGC   0.98 (+17.14%)
GE   111.67 (+0.38%)
DIS   80.78 (-0.58%)
AMC   8.24 (+8.14%)
PFE   32.72 (+0.09%)
PYPL   58.42 (+0.93%)
NFLX   383.75 (+1.04%)

Immunocore (IMCR) Stock Forecast, Price & News

$51.88
-0.16 (-0.31%)
(As of 12:20 PM ET)
Compare
Today's Range
$49.54
$51.95
50-Day Range
$49.50
$66.60
52-Week Range
$43.00
$69.06
Volume
86,372 shs
Average Volume
243,832 shs
Market Capitalization
$2.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$71.38

Immunocore MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
38.5% Upside
$71.38 Price Target
Short Interest
Bearish
6.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Immunocore in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.40) to ($1.52) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

575th out of 963 stocks

Biological Products, Except Diagnostic Industry

91st out of 160 stocks


IMCR stock logo

About Immunocore (NASDAQ:IMCR) Stock

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

IMCR Price History

IMCR Stock News Headlines

Institutions are Buying These 3 Stocks and Analysts Agree (IMCR)
Rumble (RUM), Immunocore (IMCR), and STMicroelectronics (STM) are attracting increased institutional interest, presenting potential investment opportunities.
Immunocore (NASDAQ:IMCR) PT Raised to $85.00 at Oppenheimer
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
Cardlytics, Immunocore See Activist Action
Immunocore (NASDAQ:IMCR) Trading 2.8% Higher After Analyst Upgrade
Immunocore (NASDAQ:IMCR) Upgraded at JPMorgan Chase & Co.
Immunocore (NASDAQ:IMCR) Now Covered by Needham & Company LLC
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Analyst Expectations for Immunocore Hldgs's Future
Immunocore Hldgs's Earnings Outlook
See More Headlines
Receive IMCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter.

IMCR Company Calendar

Last Earnings
8/10/2023
Today
9/25/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMCR
Fax
N/A
Employees
408
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$71.38
High Stock Price Forecast
$91.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+37.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
13 Analysts

Profitability

Net Income
$-50,990,000.00
Pretax Margin
-25.99%

Debt

Sales & Book Value

Annual Sales
$173.59 million
Book Value
$7.17 per share

Miscellaneous

Free Float
46,151,000
Market Cap
$2.55 billion
Optionable
Not Optionable
Beta
0.67
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Bahija Jallal Ph.D. (Age 61)
    CEO & Director
    Comp: $1.42M
  • Mr. Brian R. Di Donato M.B.A. (Age 56)
    CFO & Head of Strategy
  • Ms. Annelise Vuidepot Ph.D.
    CTO and Head of Pipeline & Platform Research
  • Clayton Robertson
    Head of Investor Relations
  • Ms. Lily Margaret Hepworth
    Gen. Counsel & Company Sec.
  • Ms. Amy Judge-Prein
    Chief Compliance Officer
  • Mr. Sébastien Desprez
    Head of Communications
  • Ms. Tina St. Leger (Age 55)
    Chief HR Officer & Director
  • Dr. David Berman M.D. (Age 52)
    Ph.D., Head of R&D
  • Ms. Debra Nielsen
    Chief of Staff













IMCR Stock - Frequently Asked Questions

Should I buy or sell Immunocore stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last twelve months. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IMCR shares.
View IMCR analyst ratings
or view top-rated stocks.

What is Immunocore's stock price forecast for 2023?

13 Wall Street analysts have issued 1-year price targets for Immunocore's stock. Their IMCR share price forecasts range from $16.00 to $91.00. On average, they predict the company's stock price to reach $71.38 in the next twelve months. This suggests a possible upside of 37.2% from the stock's current price.
View analysts price targets for IMCR
or view top-rated stocks among Wall Street analysts.

How have IMCR shares performed in 2023?

Immunocore's stock was trading at $57.07 at the beginning of the year. Since then, IMCR shares have decreased by 8.8% and is now trading at $52.04.
View the best growth stocks for 2023 here
.

When is Immunocore's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our IMCR earnings forecast
.

How were Immunocore's earnings last quarter?

Immunocore Holdings plc (NASDAQ:IMCR) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.03. The company earned $60.70 million during the quarter, compared to analyst estimates of $59.39 million. Immunocore had a negative net margin of 27.72% and a negative trailing twelve-month return on equity of 17.97%.

What ETFs hold Immunocore's stock?
When did Immunocore IPO?

(IMCR) raised $199 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,300,000 shares at a price of $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies acted as the underwriters for the IPO.

What is Immunocore's stock symbol?

Immunocore trades on the NASDAQ under the ticker symbol "IMCR."

Who are Immunocore's major shareholders?

Immunocore's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rock Springs Capital Management LP (6.30%), BlackRock Inc. (1.65%), Holocene Advisors LP (1.44%), Fiera Capital Corp (1.08%), Principal Financial Group Inc. (1.01%) and Braidwell LP (0.97%).

How do I buy shares of Immunocore?

Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunocore's stock price today?

One share of IMCR stock can currently be purchased for approximately $52.04.

How much money does Immunocore make?

Immunocore (NASDAQ:IMCR) has a market capitalization of $2.55 billion and generates $173.59 million in revenue each year. The company earns $-50,990,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis.

How many employees does Immunocore have?

The company employs 408 workers across the globe.

How can I contact Immunocore?

Immunocore's mailing address is 92 PARK DRIVE MILTON PARK ABINGDON, OXFORDSHIRE X0, OX14 4RY. The official website for the company is www.immunocore.com. The company can be reached via phone at 44-12-3543-8600 or via email at ir@immunocore.com.

This page (NASDAQ:IMCR) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -